Cardamonin suppresses the proliferation of colon cancer cells by promoting β-catenin degradation

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 1040-1044

  Park, Seoyoung ^a   Gwak, Jungsug ^a   Han, Seung Jin ^b   Oh, Sangtaek ^a  

^a Kookmin University   (South Korea)

^b Inje University   (South Korea)

Author keywords

catenin; Cardamonin; Colon cancer; Protein degradation

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CARDAMONIN; CYCLIN D1; MYC PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APC GENE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; ONCOGENE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHALCONES; COLONIC NEOPLASMS; DOWN-REGULATION; HUMANS;

EID: 84878869508     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00158     Document Type: Article

References (29)

1. Miller JR. The Wnts. Genome Biol., 3, reviews3001.1-reviews3001.15 (2002).
2. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol., 14, 59-88 (1998).
3. Huelsken J, Birchmeier W. New aspects of Wnt signaling pathways in higher vertebrates. Curr. Opin. Genet. Dev., 11, 547-553 (2001).
4. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Down-regulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3 β. Curr. Biol., 8, 573-581 (1998).
5. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell, 108, 837-847 (2002).
6. Latres E, Chiaur DS, Pagano M. The human F box protein β-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-catenin. Oncogene, 18, 849-854 (1999).
7. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J., 16, 3797-3804 (1997).
8. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin., 62, 10-29 (2012).
9. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta, 1653, 1-24 (2003).
10. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum. Mol. Genet., 10, 721-733 (2001).
11. Morin PJ. β-Catenin signaling and cancer. Bioessays, 21, 1021-1030 (1999).
12. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398, 422-426 (1999).
13. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science, 281, 1509-1512 (1998).
14. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the β-catenin/Tcf4 complex in human colorectal cancers. Oncogene, 21, 5861-5867 (2002).
15. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 99, 335-345 (1999).
16. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11, 1475-1489 (1983).
17. Park S, Gwak J, Cho M, Song T, Won J, Kim DE, Shin JG, Oh S. Hexachlorophene inhibits Wnt/β-catenin pathway by promoting Siah-mediated β-catenin degradation. Mol. Pharmacol., 70, 960-966 (2006).
18. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J., 16, 3797-3804 (1997).
19. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA. Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res., 61, 6563-6568 (2001).
20. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res., 9, 1291-1300 (2003).
21. Green DW, Roh H, Pippin JA, Drebin JA. β-Catenin antisense treatment decreases β-catenin expression and tumor growth rate in colon carcinoma xenografts. J. Surg. Res., 101, 16-20 (2001).
22. Foley PJ, Scheri RP, Smolock CJ, Pippin J, Green DW, Drebin JA. Targeted suppression of β-catenin blocks intestinal adenoma formation in APC Min mice. J. Gastrointest. Surg., 12, 1452-1458 (2008).
23. Qin Y, Sun CY, Lu FR, Shu XR, Yang D, Chen L, She XM, Gregg NM, Guo T, Hu Y. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro. Leuk. Res., 36, 514-520 (2012).
24. Yadav VR, Prasad S, Aggarwal BB. Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins. Br. J. Pharmacol., 165, 741-753 (2012).
25. Park MK, Jo SH, Lee HJ, Kang JH, Kim YR, Kim HJ, Lee EJ, Koh JY, Ahn KO, Jung KC, Oh SH, Kim SY, Lee CH. Novel suppressive effects of cardamonin on the activity and expression of transglutaminase-2 lead to blocking the migration and invasion of cancer cells. Life Sci., 92, 154-160 (2013).
26. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell, 7, 927-936 (2001).
27. Jaiswal AS, Marlow BP, Gupta N, Narayan S. β-Catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 21, 8414-8427 (2002).
28. Ryu MJ, Cho M, Song JY, Yun YS, Choi IW, Kim DE, Park BS, Oh S. Natural derivatives of curcumin attenuate the Wnt/β-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem. Biophys. Res. Commun., 377, 1304-1308 (2008).
29. Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun., 328, 227-234 (2005).